Replies to post #279204 on Avid Bioservices Inc (CDMO)

[exwannabe]

cjd, agree with your op cash burn numbers. And that could be kind of a feel good number if it actually goes plus..

IMO, what is more important is:

. Hit the $20M revenue (or something close). Failure to do so will cast doubts.

. Show some progress on controlling expenses.

. Hopefully (and I suspect this is not likely) show some projections on Avid III startup cost outlays remaining, and what we are looking for as total cash spend prior to break even.

I realize that most here are not in the game for Avid, but if they can show some progress on that front, the PPS will rise (as it presently trades at a discount to the Avid asset). And that will in turn result in less dilution.

[cheynew]

CJ, the following is what you have in the intro for upcoming events. Following that is something you posted that you might include in the intro, just to keep everyone informed:

Dec8: 39th San Antonio Breast Cancer Symposium” http://tinyurl.com/zb5sopc
...Dr. Bruce Freimark(Dir.Res/Preclin.Oncology) poster: “PS-Targeting Enhances Anti-LAG3 in Murine Breast Cancer Tumors”
~Dec8: FY'17Q2 (qe 10-31-16) Financials & Conf. Call - http://ir.peregrineinc.com/events.cfm
Dec11-15/Avid/Booth#209: IBC's Antibody Eng. & Therapeutics 2016”, SanDiego http://www.ibclifesciences.com/AntibodyEng/overview.xml
Feb20-22 2017: “CHI’s 5th Translational Models in Oncology & I-O”, SanFran http://www.triconference.com/Pre-Clinical-Oncology-Models
...Bruce Freimark(Dir.Res/Preclin.Oncology), “Blockade of PS-Mediated Tumor Immune Suppression to Enhance Immune Checkpoint Therapies”


Wed/12-7-16/IASLC/WCLC: UTSW’s David.Gerber to Present addl. Biomarker Data from Ph3.SUNRISE Trial. As VP Joe Shan said on 10-10-16, “We expect to be able to share the emerging [SUNRISE biomarker] data over the coming months at scientific & medical conferences as the more results become available”. The Lead author (presenter) is UTSW’s Dr. David Gerber (previously presented Ph2/NSCLC data and Prelim. SUNRISE data at AACR’14). The Senior author is Dr. Rachel E. Sanborn, Co-Director, Thoracic Oncology Pgm, Robert W. Franz Cancer Res. Center, Earle A. Chiles Res. Inst., Providence CC, Portland, OR…
Dec4-7 2016: “WCLC’16 - IASLC’s 17th World Conf. on Lung Cancer”, Vienna, Austria wclc2016.iaslc.org
“Medical doctors, scientists, nurses, health professionals, gov’t officials, partners from the industry, health advocacy group,s and patients will come together in order to obtain and exchange information on both state-of-the-art and advances in the management of lung cancer and other thoracic malignancies, considering both global and regional aspects.”
IASLC = Intl. Association for the Study of Lung Cancer - http://iaslc.org
WCLC = World Conference on Lung Cancer (IASLC)
Pgm: http://wclc2016.iaslc.org/wp-content/uploads/2016/10/WCLC-2016-Poster-Program.pdf
Poster Session with Presenters Present (ID 472) - Track: Advanced NSCLC
12/7/16 2:30-3:45pm #P3.02c-051 - ”A Pre-Treatment Serum Test Based on Complement and IL-10 Pathways Identifies Patients Benefiting from the Addition of Bavituximab to Docetaxel”
David E. Gerber [UTSW], J. Roder, N.L. Kallinteris, L. Horn, G. Losonczy, R. Natale, M. Tang, H. Roder, Joe S. Shan [VP/Clin+Reg], Rachel E. Sanborn [Providence Portland Medical Ctr]
MORE: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=126689482